DWTX
Dogwood Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.29
−2.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 16.7K | — | — | — | — |
| Gross Profit | (16.7K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 22.8M | 21.9M | 3.5M | 1.7M | 8.1M |
| SG&A Expense | 6.8M | 6.1M | 8.7M | 3.7M | 4.2M |
| General & Admin Expense | 6.8M | 6.1M | 8.7M | 3.7M | 4.2M |
| Selling & Marketing Expense | (4.0K) | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 29.5M | 28.0M | 12.2M | 5.4M | 12.3M |
| Cost and Expenses | 29.6M | 28.0M | 12.2M | 5.4M | 12.3M |
| Operating Income (EBIT) | (29.6M) | (28.0M) | (12.2M) | (5.4M) | (12.3M) |
| Non-Operating | |||||
| Interest Income | 276.3K | 96.9K | — | 150.9K | 67.5K |
| Interest Expense | — | — | 92.2K | — | — |
| Net Interest Income | 276.3K | 96.9K | (92.2K) | 150.9K | 67.5K |
| Other Non-Op Income/Expense | (8.9M) | (6.1M) | (123.0K) | 150.9K | 67.5K |
| Non-Operating Income (excl Interest) | (211.7K) | 6.1M | 30.8K | (150.9K) | (67.5K) |
| EBT (Pre-Tax Income) | (38.5M) | (34.0M) | (12.4M) | (5.3M) | (12.2M) |
| Income Tax Expense | (2.5M) | 221.1K | (503.00) | — | — |
| Bottom Line | |||||
| Net Income | (36.0M) | (34.3M) | (12.3M) | (5.3M) | (12.2M) |
| Earnings from Cont. Ops | (36.0M) | (34.3M) | (12.3M) | (5.3M) | (12.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (36.0M) | (35.5M) | (12.3M) | (5.3M) | (12.2M) |
| Per Share | |||||
| Basic EPS | ($8.95) | ($4.32) | ($12.52) | ($7.05) | ($27.66) |
| Diluted EPS | ($8.95) | ($4.32) | ($12.52) | ($7.05) | ($27.66) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 34.1M | 8.2M | 1.0M | 751071 | 442804 |
| Diluted Shares Outstanding | 34.1M | 8.2M | 1.0M | 751071 | 442804 |
| Profitability Metrics | |||||
| EBITDA | (29.3M) | (34.0M) | (12.2M) | (5.3M) | (12.2M) |
| D&A | 50.8K | 2.1K | 12.2K | — | — |
| EBIT | (29.4M) | (34.0M) | (12.3M) | (5.3M) | (12.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026